The last decade has seen remarkable progress in the understanding of the metabolic reprogramming in cancer. This has been facilitated by the ever expanding information about the complex genetic landscape in cancer tissues, which led to the identification of cancer-causing mutations in metabolic genes. In addition, advances in analytical technologies allow the exploration of metabolic networks in cancer cells with unprecedented accuracy. While the initial focus of the research into cancer metabolism has been to identify mechanisms that support nutrient acquisition and biomass production in cancer cells, more recent findings have revealed the importance of metabolic processes in preventing oxidative stress, modulating epigenetics and facilitating immune evasion. Indeed, it is becoming evident that metabolism participates in most, if not all, phenotypes that contribute to cancer development. In addition, the role of organismal metabolism in shaping the metabolic demand of cancer cells and the importance of metabolic flexibility for adaptation and treatment resistance is increasingly recognized. Moreover, different metabolic interventions, including targeted inhibition of individual transporters or enzymes, nutrient ablation strategies or dietary interventions are currently entering clinical trial. In this special issue of Molecular Metabolism, we are providing an update on recent advances in this exciting research area. Under the special topic "Cancer Metabolism e driver of the cancer phenotype and moving therapeutic target", we have collected a series of review articles that cover multiple aspects of metabolic reprogramming in cancer. Starting with the genetic programs that drive metabolic alterations in cancer cells, Matthieu Lacroix et al. discuss the metabolic functions of the p53 tumor suppressor. They do this in the context of normal tissue homeostasis and describe how deregulation of p53 contributes to metabolic disorders other than cancer. Understanding the complex metabolic functions of this important tumor suppressor in normal tissues is important to fully appreciate how its deregulation drives metabolic reprogramming in cancer. In the next article, Matthias Pietzke, Johannes Meiser and Alexei Vasquez describe the role of formate, a one-carbon molecule, that has multiple functions in cellular and organismal metabolism. They first summarize the functions of formate within the cellular metabolic network and describe its various metabolic fates. Importantly, they also discuss the potential advantage of "formate overflow" that has been identified in cancer cells. In addition, the contribution of formate metabolism to different disease states, including developmental disorders, cancer and obesity, is also discussed. Delineating the metabolic wiring in cancer cells requires state-of-the-art metabolic profiling techniques. The article by Safak Bayram et al.
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describes novel developments in metabolomics research using ultra-high resolution mass spectrometry. They discuss different approaches to study central carbon metabolism, including stable isotope labelling in steady state conditions and to determine dynamic flux. They also focus on novel strategies for the parallel determination of carbon and nitrogen flux, which is particularly important to investigate nucleotide metabolism. The next review by Valéry L. Payen et al. focuses on the role of monocarboxylate transporters in cancer. This group of transporters facilitates lactate export by glycolytic cancer cells and participates in the metabolite exchange between different populations of cancer cells and between cancer cells and the tumor stroma. The authors also discuss how lactate transporters contribute to metabolic plasticity, metabolic symbiosis, and immune invasion. Staying on the subject of nutrient transport, Javier Garcia-Bermudez et al. discuss potential strategies for the targeting of extracellular nutrient dependency in cancer. They initially define selective inhibition of nutrient transporters, treatment with metabolite-degrading enzymes and dietary intervention as potential strategies for nutrient deprivation. They describe the metabolic consequences of nutrient depletion in cancer cells and debate the challenges faced in the clinical application of these strategies in cancer therapy. They also discuss mechanisms by which cancer cells can overcome nutrient dependency through micropinocytosis. Metabolic flexibility is also the focus of the review article by Peter Kreuzaler et al., which discusses different adaptation programs used by cancer cells to respond to nutrient stress. They argue that metabolic adaptation is a major driving force in the dissemination of cancer cells by the primary tumor and the formation of metastases in different organs. They also discuss how metabolic diversity contributes to tumor heterogeneity and that metabolic adaptation defines the success of cancer treatment. The final article in this series by Daniela D. Weber et al. discusses the potential benefit of a ketogenic diet, which is high in fat but low in carbohydrates, as an adjuvant therapy for cancer treatment. The authors critically evaluate the available preclinical and clinical evidence supporting ketogenic diet and describe the mechanisms by which ketogenic diet interferes with the metabolic activity of cancer cells. They also outline strategies for the systematic evaluation of ketogenic diet as an adjuvant cancer therapy, which is a prerequisite for its application in clinical practice. We hope that this special issue provides a timely update on the recent advances in cancer metabolism research but also places the metabolic reprogramming of cancer cells into the organismal context. 
